Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting
JV Pergolizzi Jr, BK Philip, JB Leslie, R Taylor Jr… - Journal of clinical …, 2012 - Elsevier
Transdermal scopolamine, a patch system that delivers 1.5 mg of scopolamine gradually
over 72 hours following an initial bolus, was approved in the United States in 2001 for the
prevention of postoperative nausea and vomiting (PONV) in adults. Scopolamine (hyoscine)
is a selective competitive anatagonist of muscarinic cholinergic receptors. Low serum
concentrations of scopolamine produce an antiemetic effect. Transdermal scopolamine is
effective in preventing PONV versus placebo [relative risk (RR)= 0.77, 95% confidence …
over 72 hours following an initial bolus, was approved in the United States in 2001 for the
prevention of postoperative nausea and vomiting (PONV) in adults. Scopolamine (hyoscine)
is a selective competitive anatagonist of muscarinic cholinergic receptors. Low serum
concentrations of scopolamine produce an antiemetic effect. Transdermal scopolamine is
effective in preventing PONV versus placebo [relative risk (RR)= 0.77, 95% confidence …
以上显示的是最相近的搜索结果。 查看全部搜索结果